The Lancet. Microbe · 2024
Bedaquiline: what might the future hold?
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shaw Emily S, Stoker Neil G, Potter Jessica L, Claassen Helgard, Leslie Alasdair, Tweed Conor D, Chiang Chen-Yuan, Conradie Francesca, Esmail Hanif, Lange Christoph, Pinto Lancelot, Rucsineanu Oxana, Sloan Derek J, Theron Grant, Tisile Phumeza, Voo Teck Chuan, Warren Robin M, Lebina Limakatso, Lipman Marc
Аннотация
Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis, offering safer and more effective oral treatment options. However, key obstacles need to be overcome to ensure global access and prevent the rapid development of resistance against this promising class of drugs. In this Personal View, building on an international workshop held in 2023, we evaluate the current evidence and suggest possible ways forward, recognising the tension between increasing use and slowing the rise of resistance. We also discuss problems in accessing bedaquiline-containing regimens, the potential widening of their use beyond drug-resistant tuberculosis, and lessons for utilising new drugs as they are developed.